These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 27028734)

  • 1. Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference.
    McCudden C; Axel AE; Slaets D; Dejoie T; Clemens PL; Frans S; Bald J; Plesner T; Jacobs JF; van de Donk NW; Moreau P; Schecter JM; Ahmadi T; Sasser AK
    Clin Chem Lab Med; 2016 Jun; 54(6):1095-104. PubMed ID: 27028734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isatuximab-Specific Immunofixation Electrophoresis Assay to Remove Interference in Serum M-Protein Measurement in Patients with Multiple Myeloma.
    Thoren K; Menad S; Nouadje G; Macé S
    J Appl Lab Med; 2024 Jul; 9(4):661-671. PubMed ID: 38573925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of isatuximab-derived interference in serum protein electrophoresis and immunofixation, and an absence of sustained in vivo interference due to belantamab mafodotin and denosumab.
    Jimenez A; Scholl AR; Wang B; Schilke M; Carlsen ED
    Clin Biochem; 2024 May; 127-128():110761. PubMed ID: 38565341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying therapeutic monoclonal antibodies using target protein collision electrophoresis reflex assay to separate the wheat from the chaff.
    Teuwen JTJ; Ritzen LFL; Knapen-Portz YM; Ludwiczek PK; Damoiseaux JGMC; van Beers JJBC; de Boer D
    J Immunol Methods; 2023 Nov; 522():113552. PubMed ID: 37652294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Application of Hydrashift 2/4 daratumumab assay in eliminating interference of daratumumab on serum immunofixation electrophoresis].
    Xu S; Liu Y; Wen L; Zhao L; Deng X; Rong R; Lu J
    Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):840-845. PubMed ID: 34788924
    [No Abstract]   [Full Text] [Related]  

  • 6. A novel approach to remove interference of therapeutic monoclonal antibody with serum protein electrophoresis.
    Liu L; Shurin MR; Wheeler SE
    Clin Biochem; 2020 Jan; 75():40-47. PubMed ID: 31669513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evusheld, a SARS-CoV-2 spike protein-directed attachment inhibitor, appears in serum protein electrophoresis and immunofixation: a case study.
    Shah SK; Hagrass HA
    Lab Med; 2023 Nov; 54(6):e201-e203. PubMed ID: 37707512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance comparison of EasyFix G26 and HYDRASYS 2 SCAN for the detection of serum monoclonal proteins.
    Amin Nordin FD; Mohd Khalid MKN; Abdul Aziz SM; Mohamad Bakri NA; Ahmad Ridzuan SN; Abdul Jalil J; Habib A; Yakob Y
    J Clin Lab Anal; 2020 Jun; 34(6):e23254. PubMed ID: 32141626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative assessment of daratumumab in serum
    Canil G; Miolo G; Simula M; Rupolo M; Steffan A; Corona G
    Anal Methods; 2024 Jul; 16(26):4240-4246. PubMed ID: 38780038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the HYDRASHIFT 2/4 Daratumumab assay: a powerful approach to assess treatment response in multiple myeloma.
    Lee HW; Kim SM; Park HD
    Clin Chem Lab Med; 2024 Apr; ():. PubMed ID: 38630027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report.
    Murray DL; Puig N; Kristinsson S; Usmani SZ; Dispenzieri A; Bianchi G; Kumar S; Chng WJ; Hajek R; Paiva B; Waage A; Rajkumar SV; Durie B
    Blood Cancer J; 2021 Feb; 11(2):24. PubMed ID: 33563895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An up-conversion fluorescence lateral-flow immunoassay for rapid detection of Daratumumab in serum protein electrophoresis clinical samples.
    Liu Y; Tao Y; Yeung PS; Lu M; Liu J; Yu F; Shi RZ; Luo RY
    Clin Chim Acta; 2024 Jun; 559():119677. PubMed ID: 38636694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A sensitive high-resolution mass spectrometry method for quantifying intact M-protein light chains in patients with multiple myeloma.
    Muccio S; Hirtz C; Descloux S; Fedeli O; Macé S; Lehmann S; Vialaret J
    Clin Chim Acta; 2024 Jan; 552():117634. PubMed ID: 37980975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do cytomegalovirus infections affect the daratumumab treatment course in multiple myeloma patients? - Literature review.
    Ferreira LM; Cerezer JL; Gehrcke M
    Hematol Transfus Cell Ther; 2021; 43(2):185-190. PubMed ID: 32737019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daratumumab maintenance in patients with myeloma.
    Beksac M
    Lancet Oncol; 2024 Aug; 25(8):947-948. PubMed ID: 38889736
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of daratumumab on stem cell yields in patients with newly diagnosed multiple myeloma: a report from the Multiple Myeloma Group.
    Fazio F; Passucci M; Micozzi J; Di Landro F; Fianchi L; Za T; Manieri VM; Annibali O; Cupelli L; Bongarzoni V; Gentili S; De Padua L; Crisanti E; Garzia MG; Rago A; Piciocchi A; Mengarelli A; Morè S; De Stefano V; Bafti MS; Martelli M; Petrucci MT
    Bone Marrow Transplant; 2024 Jun; 59(6):896-898. PubMed ID: 38461292
    [No Abstract]   [Full Text] [Related]  

  • 17. Spencer A, Moreau P, Mateos M-V, et al. Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX. Blood Adv. 2024;8(2):388-398.
    Blood Adv; 2024 May; 8(9):2148-2150. PubMed ID: 38743411
    [No Abstract]   [Full Text] [Related]  

  • 18. Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab.
    Abdallah N; Murray D; Dispenzieri A; Kapoor P; Gertz MA; Lacy MQ; Hayman SR; Buadi FK; Gonsalves W; Muchtar E; Leung N; Dingli D; Kourelis T; Warsame R; Binder M; Kyle RA; Rajkumar SV; Kumar S
    Leukemia; 2022 May; 36(5):1426-1428. PubMed ID: 35091659
    [No Abstract]   [Full Text] [Related]  

  • 19. [Application of Modified DTT Methods to Reduce the Interference of Daratumumab on Serological Detection].
    Li YY; Zhang L; Cai K; Wu MH; Zhu LR; Li CY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Auguest; 31(5):1543-1549. PubMed ID: 37846714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Progress in the treatment of multiple myeloma with daratumumab].
    Lu J
    Zhonghua Xue Ye Xue Za Zhi; 2021 Mar; 42(3):260-264. PubMed ID: 33910316
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.